Priority 13 from the Hidradenitis Suppurativa PSP

UNCERTAINTY: How effective are oral treatments that affect the immune system (eg. Dapsone, ciclosporin, methotrexate, prednisolone) in treating Hidradenitis Suppurativa?  (JLA PSP Priority 13)
Overall ranking 13
JLA question ID 0017/13 
Explanatory note Not available for this PSP

Systematic Review: Blok JL, van Hattem S, Jonkman MF, Horváth B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. British Journal of Dermatology. 2013 Feb;168(2):243-52. doi: 10.1111/bjd.12104~PMID: 23106519

Protocol for Systematic Review: Ingram JR, Desai N, Kai AC, Chua SL, Woo P-N, Kerdel F, Burton T, Ormerod AD, Garner SE, Hood K, Piguet V. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010081. DOI: 10.1002/14651858.CD010081

Health Research Classification System category Skin
Extra information provided by this PSP
Comparison Drug
Submitted by 15 patients, 75 clinicians
Outcomes to be measured Management and or change of symptoms (pain, Hidradenitis Severity Score, time to remission and duration of remission, physician and patient assessment of change ); adverse effects* (morbidity, hospital admission), or complications (adverse effects leading to treatment discontinuation ,increased duration of treatment); acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life*; and health related costs.
*Signifies Primary outcomes
PSP information
PSP unique ID 0017
PSP name Hidradenitis Suppurativa
Total number of uncertainties identified by this PSP. 55  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 6 December 2013